Treatment regimen utilizing neratinib for breast cancer
AssigneeWyeth
InventorsAnna Berkenblit, Florence Marie Helene Binlich, Paul Goss
Life of this patent
Estimating the term…
Abstract
An extended regimen for treatment of HER-2/neu overexpressed/amplified cancer is described, with involves delivering a course of neratinib therapy to HER-2/neu overexpressed/amplified cancer patients following the completion of surgical and adjuvant therapy. The neratinib regimen may be continued for upwards of twelve months to five years. Also provided are pharmaceutical kits designed to facilitate compliance with the regimen.
Claims20
A regimen for treatment of HER-2/neu overexpressed/amplified cancer comprising delivering neratinib therapy to HER-2/neu overexpressed/amplified cancer patients at the completion of trastuzumab therapy.
A method for improving invasive disease-free survival (IDFS) or disease-free survival (DFS)-ductal carcinoma in situ (DCIS) and/or improvements in overall survival, time to distant recurrence, and/distant disease-free survival in a patient, said method comprising delivering neratinib to said patient following trastuzumab therapy.
The method according to 11, wherein the patient has received at least three cycles of trastuzumab.
The method according to 12, wherein the patient has received twelve cycles of trastuzumab.
The method according to 11, wherein the patient received standard adjuvant therapy consisting of trastuzumab and one or more chemotherapy.
The method according to 14, wherein the chemotherapy involved one or more of doxorubicin, cyclophosphamide, paclitaxel, docetaxel, carboplatin, lapatinib, pertuzimab, bevacizumab, trastuzumab-DM-1, or anthracycline based therapy.
A regimen for improving invasive disease free survival, disease-free survival-ductal carcinoma in situ, overall survival, time to distant recurrence, and/or distant disease-free survival comprising treating cancer patients with neratinib for at least one month to six months, wherein said treatment with neratinib following adjuvant therapy with trastuzumab.
Dependencies are inferred from the claim text.